Q3 EPS Estimates for Connect Biopharma Cut by HC Wainwright

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) – Stock analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for Connect Biopharma in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.30) for the quarter, down from their previous forecast of ($0.26). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.19) EPS, FY2027 earnings at ($1.03) EPS, FY2028 earnings at ($0.81) EPS, FY2029 earnings at ($0.50) EPS and FY2030 earnings at ($0.10) EPS.

Connect Biopharma (NASDAQ:CNTB) last released its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.04. The business had revenue of $2.75 million for the quarter, compared to analysts’ expectations of $0.74 million.

Several other brokerages have also commented on CNTB. Canaccord Genuity Group set a $7.00 price target on shares of Connect Biopharma in a research report on Friday. Oppenheimer assumed coverage on shares of Connect Biopharma in a research note on Thursday, July 9th. They set an “outperform” rating and a $8.00 price objective for the company. Weiss Ratings downgraded Connect Biopharma from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 30th. Piper Sandler began coverage on Connect Biopharma in a report on Friday, June 26th. They set an “overweight” rating and a $7.00 price objective for the company. Finally, Wall Street Zen raised Connect Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Connect Biopharma has a consensus rating of “Moderate Buy” and a consensus target price of $7.43.

Connect Biopharma Stock Down 2.4%

CNTB opened at $2.49 on Monday. The stock has a market capitalization of $156.77 million, a price-to-earnings ratio of -2.09 and a beta of -0.23. Connect Biopharma has a 12 month low of $1.23 and a 12 month high of $3.82. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.37 and a quick ratio of 2.37. The business has a 50-day moving average of $2.22 and a two-hundred day moving average of $2.48.

Insider Buying and Selling

In other Connect Biopharma news, Director James Huang acquired 150,000 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was bought at an average cost of $2.48 per share, for a total transaction of $372,000.00. Following the completion of the purchase, the director directly owned 13,310,000 shares in the company, valued at $33,008,800. This represents a 1.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 22.60% of the company’s stock.

Hedge Funds Weigh In On Connect Biopharma

A number of hedge funds have recently made changes to their positions in the business. ADAR1 Capital Management LLC purchased a new stake in Connect Biopharma during the 1st quarter worth $1,945,000. Richmond Brothers Inc. purchased a new position in Connect Biopharma in the fourth quarter valued at about $489,000. HRT Financial LP lifted its stake in shares of Connect Biopharma by 60.5% during the fourth quarter. HRT Financial LP now owns 16,785 shares of the company’s stock worth $47,000 after purchasing an additional 6,328 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Connect Biopharma during the fourth quarter worth about $232,000. Finally, Knott David M Jr boosted its position in shares of Connect Biopharma by 93.9% in the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after buying an additional 187,835 shares during the period. Hedge funds and other institutional investors own 58.72% of the company’s stock.

Connect Biopharma Company Profile

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.